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discounting rate of 3% was used for both costs and health outcomes simulation. 
One-way sensitivity analysis was performed. RESULTS: Therapy conversion to 
IAsp would result in increased life expectancy by 0.81 years per patient (13.93 vs. 
13.12) and QALY by 1.44 QALYs per patient (9.87 vs. 8.43), due to reduced 
incidences of diabetes-related complications. Treatment and management costs 
of diabetes were increased by CNY (Chinese Yuan) 11,690 (48,850 vs. 37,160) and 
1,982 (39,924 vs. 37,942) respectively. However, the costs of complications, 
including cerebrovascular disease, renal complications, ulcer/amputation/ 
neuropathy, eye complications, and hypoglycemia events, were reduced by CNY 
199,028 (102,590 vs. 301,618), resulting in total direct medical cost saving of CNY 
185,357. Sensitivity analyses demonstrated robustness of the results. 
CONCLUSIONS: Switching from HI to IAsp in T2DM patients in China was 
associated with not only improvement of life expectancy and QALYs, but also 
significant reduction in total direct medical costs. Therapy conversion to IAsp 
from HI is a cost-saving treatment strategy for T2DM patients in a Chinese 
setting.  
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OBJECTIVES: To assess the cost-effectiveness (CE) of starting insulin detemir 
(IDet) ± oral glucose-lowering drugs (OADs) in people with type 2 diabetes (T2D) 
in countries in different economic circumstances based on observational data 
gathered in routine clinical practice. METHODS: The A1chieve® study assessed 
safety and outcomes over 24 weeks in 66,726 people with T2D starting insulin 
analog therapy. The CE analyses included people starting IDet in Algeria (n=473), 
India (n=1,491), Mexico (n=101), Indonesia (n=109), South Korea (n=487) and in 
Malaysia based on people in 4 ASEAN countries (n=456). Data were collected on 
clinical effectiveness, adverse events, and patient reported outcomes using the 
EQ-5D questionnaire. CE analyses used the IMS CORE diabetes model with 1 and 
30 year time horizons, with country-specific costs for complications and 
therapies and background mortality rates. Incremental cost-effectiveness ratios 
(ICER) are expressed as cost/QALY in local currencies, USD and fractions of local 
GDP per capita based on starting IDet. CE was pre-defined as <3*GDP. RESULTS: 
One-year ICERs were Algeria (DZD 617,658; USD 7,758; GDP 1.48), India (INR 
58,454; USD 1,054; GDP 0.71), Mexico (MXN 62,952; USD 4,835; GDP 0.48), 
Indonesia (IDR 22,920,222; USD 2,381; GDP 0.68), South Korea (KRW 4,273,409; 
USD 3,935; GDP 0.18), Malaysia (MYR 17,613; USD 5,758; GDP 1.34). 30-year ICERs 
were: Algeria (DZD 368,200; USD 4,625; GDP 0.88), India (INR 39,214; USD 707, GDP 
0.48), Mexico (MXN -2,887; USD -222; GDP -0.02); Indonesia (IDR 3,995,329; USD 
415; GDP 0.12), South Korea (KRW 15,139; USD 14, GDP 0.00) and Malaysia (MYR 
10,499; USD 3,432; GDP 0.80). Sensitivity analyses on the 30 year time horizon 
showed the findings to be robust. CONCLUSIONS: Starting IDet in T2D as 
performed in the A1chieve® study was found to be cost-effective across all 
country settings based on a 1 and 30 year time horizon.  
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OBJECTIVES: To assess the cost-effectiveness (CE) of switching from biphasic 
human insulin 30 (BHI 30) ± oral glucose-lowering drugs (OADs) to biphasic 
insulin aspart 30 (BIAsp 30) ± OADs in people with type 2 diabetes (T2D) in 
countries in different economic circumstances based on observational data 
gathered in routine clinical practice. METHODS: The A1chieve® study assessed 
safety and outcomes over 24 weeks in 66,726 people with T2D starting insulin 
analog therapy. The CE analyses included people switching to BIAsp 30 in Saudi 
Arabia (n=401), India (n=866) and Indonesia and Malaysia based on people in 4 
ASEAN countries (n=175). Data were collected on clinical effectiveness, adverse 
events, and outcomes using the EQ-5D questionnaire. CE analyses used the IMS 
CORE diabetes model with 1 and 30 year time horizons, with country-specific 
costs for complications and therapies and background mortality rates. 
Incremental cost-effectiveness ratios (ICERs) are expressed as cost/QALY in local 
currencies, USD and in fractions of local GDP per capita based on switching from 
BHI 30 to BIAsp 30. CE was pre-defined as <3*GDP. RESULTS: One-year ICERs 
were: Saudi Arabia (SAR 12,913; USD 3,443; GDP 0.17), India (INR 36,001; USD 649; 
GDP 0.44), Indonesia (IDR 120,507,714; USD 12,520; GDP 2.92), Malaysia (MYR 
40,321; USD 13,180; GDP 3.08). 30-year ICERs were: Saudi Arabia (SAR 837; USD 
223; 0.03 GDP), India (INR 21,696; USD 391, GDP 0.26), Indonesia (IDR 51,416,633; 
USD 5,342; GDP 1.25), Malaysia (MYR 19,967; USD 5,342; GDP 1.25). Sensitivity 
analyses on the 30 year time horizon showed the findings to be robust. 
CONCLUSIONS: Switching from BHI 30±OADs to BIAsp 30±OADs in T2D as 
performed in the A1chieve® study was found to be cost-effective across all 
country settings at 1 and 30 year time horizons. The Malaysian analyses showed 
borderline cost-effectiveness using 1 year time horizon but cost-effectiveness 
assuming 30 year time horizon.  
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OBJECTIVES: To assess the cost-effectiveness (CE) of switching therapy from 
insulin glargine (IGlar) ± oral glucose-lowering drugs (OADs) to biphasic insulin 
aspart 30 (BIAsp 30) ± OADs in people with type 2 diabetes (T2D) in Saudi Arabia 
and India based on observational data gathered in routine clinical practice. 
METHODS: The A1chieve® study assessed safety and outcomes over 24 weeks in 
66,726 people with T2D starting insulin analog therapy. Most participants (96%) 
stated better glycemic control as reason to switch therapy, 31% also stated 
problems with hypoglycemia as reason of switch. The CE analyses included 
people switching to BIAsp 30 in Saudi Arabia based on people in 7 Gulf countries 
(n=103) and in India (n=191). Data were collected on clinical effectiveness, 
adverse events, and patient reported outcomes using the EQ-5D questionnaire. 
CE analyses used the IMS CORE diabetes model with 1 and 30-year time horizons, 
with country-specific costs for complications and therapies and country-specific 
background mortality rates. Incremental cost-effectiveness ratios (ICERs) are 
expressed as cost/QALY in local currencies, USD and in fractions of local GDP per 
capita based on switching from IGlar to BIAsp 30. CE was pre-defined as <3*GDP. 
RESULTS: For both a 1 and 30 year time horizons the switch was found to be less 
costly and have better outcomes. 1-year ICERs were: Saudi Arabia (SAR -8,958; 
USD -2,388; GDP -0.12) and India (INR -60,194; USD -1,086; GDP -0.73). 30-year 
ICERs were: Saudi Arabia (SAR -14,242; USD -3,798; GDP -0.19) and India (INR  
-55,914; USD -1,008; GDP -0.68). Sensitivity analyses on the 30 year time horizon 
showed the findings to be robust. CONCLUSIONS: Switching therapy from IGlar 
to BIAsp 30 in T2D as performed in the A1chieve® study was found to be 
dominant across both country settings based on a 1 and 30 year time horizon.  
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OBJECTIVES: To assess the cost-effectiveness (CE) of starting biphasic insulin 
aspart 30 (BIAsp 30) therapy ± oral glucose-lowering drugs (OADs) in people with 
type 2 diabetes (T2D) in countries in different economic circumstances based on 
observational data gathered in routine clinical practice. METHODS: The 
A1chieve®study assessed safety and outcomes over 24 weeks in 66,726 people 
with T2D starting insulin analog therapy. The CE analyses included people 
starting BIAsp 30 in Saudi Arabia (n=901), India (n=7,546), Indonesia (n=153), in 
Malaysia based on people in 4 ASEAN countries (n=430) and in Algeria based on 
people in 3 countries in North-West Africa (n=279). Data were collected on 
clinical effectiveness, adverse events, and patient reported outcomes using the 
EQ-5D questionnaire. CE analyses used the IMS CORE diabetes model with 1 and 
30 year time horizons, with country-specific costs for complications and 
therapies and background mortality rates. Incremental cost-effectiveness ratios 
(ICER) are expressed as cost/QALY in local currencies, USD and in fractions of 
local GDP per capita based on starting BIAsp 30. CE was pre-defined as <3*GDP. 
RESULTS: 1-year ICERs were: Saudi Arabia (SAR 10,741; USD 2,864; GDP 0.14), 
India (INR 35,182; USD 635; GDP 0.43), Indonesia (IDR 40,487,477; USD 4,207; GDP 
1.2), Malaysia (MYR 13,061; USD 4,270; GDP 1.00), Algeria (DZD 246,422; USD 3,095, 
GDP 0.73). 30-year ICERs were: Saudi Arabia (SAR -3,004; USD -801; GDP -0.04), 
India (INR 20,516; USD 370; GDP 0.25), Indonesia (IDR 15,710,332; USD 1,632; GDP 
0.47), Malaysia (MYR 8,038; USD 2,627; GDP 0.61), Algeria (DZD 155,659; USD 1,955; 
GDP 0.46). Sensitivity analyses on the 30 year time horizon showed the findings 
to be robust. CONCLUSIONS: Starting BIAsp 30 in T2D as performed in the 
A1chieve® study was found to be cost-effective across all country settings based 
on a 1 and 30 year time horizon.  
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OBJECTIVES: To evaluate long-term health economic outcomes of switching 
from human soluble insulin (HI) to insulin aspart (IAsp) on a basal-bolus regimen 
in type 2 diabetes mellitus (T2DM) patients in a Chinese setting. METHODS: The 
previously published and validated IMS Core Diabetes Model was used to project 
long-term life expectancy, quality-adjusted life years (QALY) and total direct 
medical costs. Baseline patient characteristics and treatment effects were based 
on Asian subgroup (n=185, countries including China, Bangladesh, India, 
Pakistan, Indonesia, South Korea, Malaysia, Philippines, Singapore and Taiwan) 
in A1chieve study which is a prospective, multi-centre, open-label, non-
